Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
VANCOUVER, British Columbia, April 26, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 2018 Bloom Burton & Co. Healthcare Conference in Toronto on Thursday, May 3rd 2018.
Aquinox Presentation Details
Date: Thursday, May 3rd 2018
Time: 7:30 am Pacific Time / 10:30 am Eastern Time
Location: Toronto, ON – Sheraton Centre Hotel Toronto
A live audio webcast and archive of the event will be available at:
http://wsw.com/webcast/bloomburton3/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit http://www.aqxpharma.com/.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
